Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia (Q37896015)

25 August 2017

1 reference

title

Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia (English)

1 reference

25 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

Jerald P Radich

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

29 June 2011

1 reference

25 August 2017

number of pages

12

1 reference

inferred from page(s)

published in

Cancer

1 reference

25 August 2017

volume

118

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

300-311

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using str

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Defining and managing imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

7 January 2021

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

7 January 2021

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

7 January 2021

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26280

7 January 2021

Identifiers

DOI

10.1002/CNCR.26280

1 reference

25 August 2017

1 reference